---
title: "Two-year BIOPACT randomised controlled trial analysis demonstrates “persistent excellence” for low-profile Passeo-18 Lux DCB"
date: "2023-11-27T11:51:34.000Z"
publishedDate: "27 novembre 2023"
summary: "Biotronik has announced the presentation of two-year results from the investigator-initiated BIOPACT randomised controlled trial (RCT) by principal investigator Koen Deloose (AZ Sint-Blasius Hospital, Dendermonde, Belgium) at the Paris Vascular Insights (PVI) 2023 congress (8–10 November, Paris, France). The randomised controlled non-inferiority trial evaluated the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) [&#8230;] The post Two-year BIOPACT randomised controlled trial analysis demonstrates &#8220;persistent excellence&#8221; for low-profile Passeo-18 Lux DCB appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/two-year-biopact-randomised-controlled-trial-analysis-demonstrates-persistent-excellence-for-low-profile-passeo-18-lux-dcb/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2023-11-27-two-year-biopact-randomised-controlled-trial-analysis-demonstrates-persistent-excellence-for-low-profile-passeo-18-lux-dcb"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2023/09/bio27664-passeo-18-lux.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/two-year-biopact-randomised-controlled-trial-analysis-demonstrates-persistent-excellence-for-low-profile-passeo-18-lux-dcb/"
---

![Two-year BIOPACT randomised controlled trial analysis demonstrates “persistent excellence” for low-profile Passeo-18 Lux DCB](https://vascularnews.com/wp-content/uploads/sites/7/2023/09/bio27664-passeo-18-lux.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/two-year-biopact-randomised-controlled-trial-analysis-demonstrates-persistent-excellence-for-low-profile-passeo-18-lux-dcb/*

## L’essentiel

Biotronik has announced the presentation of two-year results from the investigator-initiated BIOPACT randomised controlled trial (RCT) by principal investigator Koen Deloose (AZ Sint-Blasius Hospital, Dendermonde, Belgium) at the Paris Vascular Insights (PVI) 2023 congress (8–10 November, Paris, France). The randomised controlled non-inferiority trial evaluated the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) [&#8230;] The post Two-year BIOPACT randomised controlled trial analysis demonstrates &#8220;persistent excellence&#8221; for low-profile Passeo-18 Lux DCB appeared first on Vascular News .

## Lien source

https://vascularnews.com/two-year-biopact-randomised-controlled-trial-analysis-demonstrates-persistent-excellence-for-low-profile-passeo-18-lux-dcb/
